Molecular Genetics & Genomic Medicine: New Open Access Journal Launched by Wiley
News Nov 06, 2012
Dr. Muenke, a renowned medical geneticist, trained in pediatrics in his native Germany and then pursued postdoctoral fellowship training in human and clinical genetics at Yale and the University of Pennsylvania. He is now based at a leading research organization in Bethesda, USA.
Dr. Muenke’s group identified several genes important in craniofacial disorders including one of the most common, now termed Muenke syndrome. More recently, his lab has identified susceptibility genes for the most common childhood behavioral disorder, Attention-Deficit/Hyperactivity Disorder (ADHD), with further research focused on predicting severity, treatment, and long-term outcome.
Working alongside an international editorial board of experts in diverse areas of human and medical genetics and genomics, Dr. Muenke will oversee the rigorous peer-review and evaluation of articles submitted for publication in MGGM.
“I am extremely excited about being the founding editor of this new journal,” says Dr. Muenke. “Since there is not a single disorder that does not have a genetic origin, I believe that the fields of molecular genetics and genomic medicine will be expanding into virtually all medical specialties. MGGM will grow as well, with articles on diseases from diagnosis to treatment, as a step toward personalized medicine.”
Molecular Genetics & Genomic Medicine is the latest addition to Wiley’s portfolio of genetics journals and will benefit from relationships with widely respected titles including the American Journal of Medical Genetics and Human Mutation.
“We’re delighted to expand our open access portfolio with the addition of this important new journal,” said Rachel Burley, Vice President and Director, Open Access, Wiley. “Under the expert editorial leadership of Dr. Muenke, Molecular Genetics & Genomic Medicine will make a valuable contribution to the literature.”
The journal is open to submissions now and will publish online in spring 2013. Please visit the journal’s website www.MGGMjournal.com for further information and future updates.
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE